U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07247357) titled 'A Study of LY4064809 in Healthy Adult Chinese Participants' on Nov. 18.
Brief Summary: The main purpose of this study is to measure how much LY4064809 gets into the bloodstream and how long it takes the body to eliminate it in healthy participants. It also looks at safety and tolerability in healthy participants. The study drug will be administered orally. The study will last approximately 21 days, excluding screening.
Study Start Date: Oct. 24
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: LY4064809
administered orally
Recruitment Status: RECRUITING
Sponsor: Eli Lilly and Company
Disclaimer: Curated by ...